Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | VET3-TGI |
Synonyms | |
Therapy Description |
VET3-TGI is an oncolytic vaccinia virus engineered to express CXCR3, IL-12 and an anti-TGFB1 mini-monomer, which may increase antitumor immune response (Journal for ImmunoTherapy of Cancer 2022;10). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
VET3-TGI | VET3TGI|VET3 TGI | VET3-TGI is an oncolytic vaccinia virus engineered to express CXCR3, IL-12 and an anti-TGFB1 mini-monomer, which may increase antitumor immune response (Journal for ImmunoTherapy of Cancer 2022;10). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06444815 | Phase I | VET3-TGI Pembrolizumab + VET3-TGI | A Study of VET3-TGI in Patients With Solid Tumors (STEALTH-001) | Recruiting | USA | 0 |